332 related articles for article (PubMed ID: 26238720)
1. Incidence of narcolepsy before and after MF59-adjuvanted influenza A(H1N1)pdm09 vaccination in South Korean soldiers.
Kim WJ; Lee SD; Lee E; Namkoong K; Choe KW; Song JY; Cheong HJ; Jeong HW; Heo JY
Vaccine; 2015 Sep; 33(38):4868-72. PubMed ID: 26238720
[TBL] [Abstract][Full Text] [Related]
2. No association between influenza A(H1N1)pdm09 vaccination and narcolepsy in South Korea: an ecological study.
Choe YJ; Bae GR; Lee DH
Vaccine; 2012 Dec; 30(52):7439-42. PubMed ID: 23088885
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the adverse events associated with MF59-adjuvanted and non-adjuvanted H1N1 vaccines in healthy young male Korean soldiers.
Hwang SM; Kim HL; Min KW; Kim M; Lim JS; Choi JM; Chun BC; Kim MJ; Lee SM; Kim SY; Jeon HH
Jpn J Infect Dis; 2012; 65(3):193-7. PubMed ID: 22627298
[TBL] [Abstract][Full Text] [Related]
4. Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy.
Tsai TF; Crucitti A; Nacci P; Nicolay U; Della Cioppa G; Ferguson J; Clemens R
Scand J Infect Dis; 2011 Sep; 43(9):702-6. PubMed ID: 21534891
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
[TBL] [Abstract][Full Text] [Related]
7. In vitro assessment of the allergenicity of novel MF59-adjuvanted pandemic H1N1 influenza vaccine produced in dog kidney cells.
Bencharitiwong R; Leonard S; Tsai T; Nowak-Węgrzyn A
Hum Vaccin Immunother; 2012 Jul; 8(7):863-5. PubMed ID: 22777093
[TBL] [Abstract][Full Text] [Related]
8. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.
Ahmed SS; Schur PH; MacDonald NE; Steinman L
J Autoimmun; 2014 May; 50():1-11. PubMed ID: 24559657
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine.
Rouleau I; De Serres G; Drolet JP; Skowronski DM; Ouakki M; Toth E; Landry M; Ménard S; Gagnon R
Vaccine; 2013 Dec; 31(50):5989-96. PubMed ID: 24144473
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
[TBL] [Abstract][Full Text] [Related]
11. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations.
Banzhoff A; Haertel S; Praus M
Hum Vaccin; 2011 May; 7(5):539-48. PubMed ID: 21422814
[TBL] [Abstract][Full Text] [Related]
12. A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
Reisinger KS; Holmes SJ; Pedotti P; Arora AK; Lattanzi M
Hum Vaccin Immunother; 2014; 10(8):2395-407. PubMed ID: 25424947
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
Knuf M; Leroux-Roels G; Rümke H; Rivera L; Pedotti P; Arora AK; Lattanzi M; Kieninger D; Cioppa GD
Hum Vaccin Immunother; 2015; 11(2):358-76. PubMed ID: 25621884
[TBL] [Abstract][Full Text] [Related]
14. Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec.
Montplaisir J; Petit D; Quinn MJ; Ouakki M; Deceuninck G; Desautels A; Mignot E; De Wals P
PLoS One; 2014; 9(9):e108489. PubMed ID: 25264897
[TBL] [Abstract][Full Text] [Related]
15. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.
Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli C; Groth N; Levin Y; Del Giudice G
Hum Vaccin Immunother; 2014; 10(6):1701-10. PubMed ID: 24732325
[TBL] [Abstract][Full Text] [Related]
16. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months.
Esposito S; Pugni L; Daleno C; Ronchi A; Valzano A; Serra D; Mosca F; Principi N
Pediatrics; 2011 May; 127(5):e1161-8. PubMed ID: 21464195
[TBL] [Abstract][Full Text] [Related]
17. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine.
Cheong HJ; Song JY; Heo JY; Noh JY; Choi WS; Park DW; Wie SH; Kim WJ
Clin Vaccine Immunol; 2011 Aug; 18(8):1358-64. PubMed ID: 21715575
[TBL] [Abstract][Full Text] [Related]
19. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns.
Wijnans L; Lecomte C; de Vries C; Weibel D; Sammon C; Hviid A; Svanström H; Mølgaard-Nielsen D; Heijbel H; Dahlström LA; Hallgren J; Sparen P; Jennum P; Mosseveld M; Schuemie M; van der Maas N; Partinen M; Romio S; Trotta F; Santuccio C; Menna A; Plazzi G; Moghadam KK; Ferro S; Lammers GJ; Overeem S; Johansen K; Kramarz P; Bonhoeffer J; Sturkenboom MC
Vaccine; 2013 Feb; 31(8):1246-54. PubMed ID: 23246544
[TBL] [Abstract][Full Text] [Related]
20. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus.
Zuccotti GV; Pariani E; Scaramuzza A; Santoro L; Giani E; Macedoni M; Gazzarri A; Anselmi G; Amendola A; Zanetti A
Diabet Med; 2011 Dec; 28(12):1530-6. PubMed ID: 21916971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
